|
 
 
Thrombosis Research Section Faculty
Faculty (Secondary Appointment)
Research Interests:
W. Keith Hoots, M.D. is Professor of Pediatrics and Division Head/Pediatric
Hematology University of Texas Medical School at Houston; Section
Head Pediatric Hematology, University of Texas M.D. Anderson Cancer
Center; and Medical Director, Gulf State Hemophilia and Thrombophilia
Treatment Center. Dr. Hoots also directs the Fellowship Program at
M.D. Anderson. Dr. Hoots is a past president of the Hemophilia Research
Society of North America. Currently, he is a member of the U.S. Department
of Health and Human Services Blood Safety and Availability Advisory
Committee to the Secretary of Health, chair of the Medical and Scientific
Advisory Committee for the National Hemophilia Foundation and subcommittee
co-chair of the DIC Subcommittee of International Society of Thrombosis
and Hemostasis. Dr. Hoots is an associate editor for Seminars in Thrombosis
and Hemostasis and serves on the editorial boards of Haemophilia ,
Haemophilia Forum and the International Monitor on Hemophilia and
reviews for many journals. He has also published numerous journal
articles, textbook chapters and abstracts primarily in the discipline
of hemostasis and thrombosis. Dr. Hoots' major interests involve the
management and diagnosis of congenital and acquired bleeding disorders
and clotting disorders. His work includes the creation of and longitudinal
follow-up of hemophilia cohorts with HIV and hepatitis, gene therapy
trials for Hemophilia A and B, clinical trials of new clotting concentrates
for Hemophilia A and B, and the impact of care and clotting factor
product on Hemophilia patient outcome. He also has a 20 year interest
in the diagnosis and treatment of diffuse intravascular coagulation
(DIC), in particular DIC in head trauma. Dr. Hoots' trainees would
perform clinical research in the area of hemophilia or DIC.
Selected Publications:
1. Hoots WK, Leissinger C, Stabler S, et al. Continuous intravenous
infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia
B. Haemophilia 2003; 9:164-72.
2. Vadhan-Raj S, Kavanagh JJ, Freedman RS, Folloder J, Currie LM,
Bueso-Ramos C, Verschraegen CF, Narvios AB, Connor J, Hoots WK, et
al: Safety and efficacy of transfusions of autologous cryopreserved
platelets derived from recombinant human thrombopoietin to support
chemotherapy-associated severe thrombocytopenia. The Lancet.
359:2145-2152, 2002.
3. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, Goedert
JJ, Buchbinder S, Hoots WK, Vlahov D, O'Brien SJ, Carrington M: Effect
of a Single Amino Acid change in MHC Class I Molecules on the Rate
of progression to AIDS. New England Journal of Medicine, 344:
1668-1675, 2001.
4. Fischer G, Hoots WK, Abrams C: Viral Reduction Techniques: Types
and Purpose. Transfusion Medicine Reviews April 2001, Vol.
15, No. 2, Suppl. 1.
5. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition,
clinical and laboratory criteria, and a scoring system for disseminated
intravascular coagulation. Thromb Haemost. 2001;86:1327-30.
6. Hoots WK, Abrams C, Tankersleydagger D. The impact of Creutzfeldt-Jakob
disease and variant Creutzfeldt-Jakob disease on plasma safety. Transfus
Med Rev. 2001;15 (2 Suppl 1):45-59.
7. Hoots WK, Abrams C, Tankersley D. The Food and Drug Administration's
perspective on plasma safety. Transfus Med Rev. 2001;15 (2
Suppl 1):20-6.
 ©1995-2003
Baylor College of Medicine
Email: medicine@bcm.tmc.edu
URL: http://public.bcm.tmc.edu/medicine/hoots.htm (Modified: June 4, 2003)
|